Valuation: BioNTech SE

Market Cap 21.35B 24.03B 20B 18.11B 34.15B 2,316B 34.42B 240B 93.33B 1,182B 90.2B 88.27B 3,801B P/E 2026 *
-14.9x
P/E 2027 * -15.6x
Enterprise Value 9.98B 11.24B 9.35B 8.46B 15.96B 1,083B 16.09B 112B 43.63B 552B 42.16B 41.26B 1,777B EV / Sales 2026 *
5.52x
EV / Sales 2027 * 6.25x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.96%
1 week-3.38%
Current month-2.61%
1 month-7.74%
3 months-1.86%
6 months+4.99%
Current year+0.56%
1 week 95.2
Extreme 95.2
100.02
1 month 95.2
Extreme 95.2
103
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
374.58
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 31/12/2017
Chief Executive Officer 61 01/06/2008
Director of Finance/CFO - 30/06/2025
Director TitleAgeSince
Chairman 56 01/06/2008
Director/Board Member 69 01/06/2008
Director/Board Member 65 31/12/2017
Date Insider Type Main position Quantity % Market Cap. Importance
02/10/26 Sell

Chief Executive Officer

-17,000 0.0070%
30/09/26 Sell

Chief Executive Officer

-32,000 0.0132%
28/09/26 Sell

Chief Executive Officer

-34,000 0.0141%
Change 5-day change 1-year change 3-year change Capi.($)
-1.96%-3.38%-9.25%-12.85% 24.53B
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-0.93%+327.90%+691.25% 44.51B
-2.30%-4.06%+25.82%+31.42% 43.8B
+0.31%-1.15%+5.50%+112.56% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
+1.35%-10.57%-33.04%+320.25% 22.67B
Average +0.52%-1.36%+43.99%+145.07% 41.62B
Weighted average by Cap. +0.80%-1.11%+51.70%+144.34%

Financials

2026 *2027 *
Net sales 1.81B 2.03B 1.69B 1.53B 2.89B 196B 2.91B 20.31B 7.9B 100B 7.63B 7.47B 322B 1.81B 2.04B 1.7B 1.54B 2.9B 197B 2.92B 20.36B 7.92B 100B 7.65B 7.49B 322B
Net income -1.38B -1.55B -1.29B -1.17B -2.2B -149B -2.22B -15.47B -6.02B -76.19B -5.82B -5.69B -245B -1.31B -1.48B -1.23B -1.11B -2.1B -142B -2.11B -14.73B -5.73B -72.53B -5.54B -5.42B -233B
Net Debt -11.37B -12.8B -10.65B -9.64B -18.19B -1,234B -18.33B -128B -49.7B -629B -48.03B -47.01B -2,024B -10.03B -11.29B -9.39B -8.51B -16.04B -1,088B -16.17B -113B -43.84B -555B -42.37B -41.46B -1,786B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
06/10/26 US$95.73 -1.96% 882,678
05/10/26 US$97.64 +0.76% 1,437,531
02/10/26 US$96.90 +0.05% 696,033
01/10/26 US$96.85 -1.48% 820,114
30/09/26 US$98.30 -0.27% 845,547
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Ratings Surperformance© - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
84.98EUR
Average target price
103.29EUR
Spread / Average Target
+21.55%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioNTech SE
  1. Stock Market
  2. Stocks
  3. BNTX Stock